Updated on 18.05.2026|7:40 PM
Bio Medica Laboratories Limited is set to launch its Initial Public Offering (IPO). It is a contract manufacturer (B2B) specializing in generic pharmaceutical parenteral formulations such as Liquid and Dry Powder Injections.
The public issue will open for subscription on Thursday, May 21, 2026, and close on Monday, May 25, 2026.
Through this book-built offering, the company aims to raise approximately ₹52.43 Crores at the price band of ₹132 – ₹139 per share. Track all the IPOs of 2026 in our latest IPOs section.
The issue comprises a Fresh Issue of ₹47.19 Crores and an Offer for Sale (OFS) of ₹5.24 Crores, with proceeds targeted at capacity expansion and debt repayment.
In this article, you will find Bio Medica Laboratories IPO GMP today, price band, and a detailed review with financials and valuations.
Briefs of Bio Medica Laboratories IPO Details:
- Price Band: ₹132 – ₹139 per equity share
- Face Value: ₹10 per share
- IPO Open / Close Dates: May 21, 2026 – May 25, 2026
- Lot Size: 1,000 Shares (Note: Retail Minimum Application is 2 Lots / 2,000 Shares)
- Issue Size: 37,72,000 Equity Shares / ~₹52.43 Crores
- Fresh Issue: 33,95,000 Shares (~₹47.19 Cr)
- Offer for Sale (OFS): 3,77,000 Shares (~₹5.24 Cr)
- Registrar: Skyline Financial Services Pvt. Ltd.
- Listing Exchange: NSE SME
IPO Reservation:
The offering comprises a total issue size of 37,72,000 shares. The net offer to the public is 35,83,000 shares, allocated as follows:
- QIB Portion: Up to 36,000 Equity Shares. (Note: There is no Anchor Investor participation).
- NII (HNI) Portion: Not less than 17,55,000 Equity Shares.
- Retail (RII) Portion: Not less than 17,92,000 Equity Shares.
- Market Maker: 1,89,000 Equity Shares.
What Is The Bio Medica Laboratories IPO GMP Today?
Monitor current trends for upcoming IPOs on our central GMP hub.
Please keep in mind that the Grey Market Premium (GMP) is completely unofficial and lacks regulation by SEBI, NSE, or BSE. Because these premiums fluctuate daily based on speculative demand, investors must look beyond GMP and analyze core company financials before deploying capital.
What Are The Important Bio Medica Laboratories IPO Dates & Allotment Schedule?
For investors planning their capital allocation, here is the critical timeline for the issue:
- IPO Open Date: Thursday, May 21, 2026
- IPO Close Date: Monday, May 25, 2026
- Basis of Allotment Date: Tuesday, May 26, 2026
- Refund Initiation Date: Wednesday, May 27, 2026
- Credit of Shares: Wednesday, May 27, 2026
- Listing Date: Friday, May 29, 2026
What Are The Objectives of Bio Medica Laboratories IPO?
The company proposes to utilize the Net Proceeds from the Fresh Issue towards the following strategic purposes:
- Capacity Expansion: A significant allocation of ₹28.50 Crores is earmarked for setting up a new manufacturing facility at its existing Unit-II. This includes civil construction and the purchase of new plant and machinery to scale up operations.
- Debt Repayment: The company plans to use ₹6.50 Crores to prepay or repay outstanding borrowings, which will help reduce interest burdens and improve financial leverage.
- General Corporate Purposes: The remaining balance will be used for strategic initiatives, brand building, and meeting ongoing business exigencies.
(Note: The company will not receive any proceeds from the Offer for Sale).
How is The Financial Performance of Bio Medica Laboratories?
The following table summarizes the financial performance of the company based on restated financial statements.
(Figures in ₹ Crores)
Particulars | Period Ended 30 Nov 25 (8M) | FY 2024-25 | FY 2023-24 | FY 2022-23 |
Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
Profit After Tax (PAT) | 8.66 | 9.79 | 2.50 | 0.33 |
EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Assets | 65.17 | 39.12 | 19.53 | 17.57 |
Source: RHP
Financial Analysis & Observations:
Total Income:
The company demonstrated exceptional revenue scaling, growing by over 150% from ₹15.34 Crores in FY24 to ₹38.33 Crores in FY25.
This surge was primarily driven by the commencement of its fully compliant Unit-2 and the successful receipt of product approvals for high-value injectable vials.
Profit After Tax (PAT):
Profitability witnessed an extraordinary turnaround, with PAT skyrocketing from ₹0.33 Crores in FY23 to ₹9.79 Crores in FY25.
The PAT margin expansion to 25.64% in FY25 reflects significant operational leverage and cost optimization in packaging.
EBITDA:
Operational efficiency improved markedly, with EBITDA jumping to ₹15.21 Crores in FY25.
The impressive EBITDA margin of 39.83% in FY25 highlights the company's strong pricing power and the lucrative nature of specialized generic injectables.
Total Borrowing:
To support aggressive capacity expansion and working capital needs, total borrowings escalated sharply to ₹38.17 Crores by November 2025.
The planned IPO debt repayment of ₹6.50 Crores will be crucial in managing this leverage.
Assets:
The asset base nearly tripled from ₹19.53 Crores in FY24 to ₹65.17 Crores by November 2025.
This rapid asset accumulation underscores the heavy capital expenditure deployed to establish and equip new manufacturing capabilities.
What Are the P/E Ratio and Peer Comparison?
Based on its Fiscal Year 2026 earnings per share (EPS) of ₹10.67, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 13.02x at the upper end of the price band (₹139).
P/E Ratio = ₹139(Price) / ₹10.67 (Earnings Per Share)
P/E Ratio ≈ 13.02x
Peer Comparison Table (FY 2024-25 Data):
Company | P/E Ratio | RoNW (%) | EPS (₹) | NAV (₹) |
Bio Medica Laboratories | 13.02 | 99.59 | 10.67 | 16.05 |
Shukra Pharmaceuticals Ltd | 47.57 | 15.90 | 0.22 | 1.43 |
Zenotech Laboratories Ltd | N/A | 6.01 | 0.92 | 15.76 |
Analysis:
Bio Medica Laboratories is entering the market at a P/E multiple of approximately 13.02x based on its FY25 EPS. When compared to the industry average P/E of ~23.78x and its listed peer Shukra Pharmaceuticals (47.57x), the issue appears to be priced at a significant discount.
Furthermore, Bio Medica boasts an exceptionally superior Return on Net Worth (RoNW) of 99.59%, massively outperforming its peers, which suggests highly efficient capital utilization within its high-margin injectables niche.
What is The Industry Outlook of Bio Medica Laboratories?
Growth Potential:
The Indian pharmaceutical contract manufacturing sector is experiencing robust tailwinds, driven by the global demand for cost-effective generic formulations and the "China Plus One" sourcing strategy.
Market Trends:
There is a growing emphasis on specialized parenteral (injectable) formulations, which require stringent compliance and advanced manufacturing capabilities, creating a high barrier to entry that favors established players like Bio Medica.
What Are The Strengths and Risks of Bio Medica Laboratories IPO?
Strengths:
- Exceptional Profitability: A RoNW of nearly 100% and EBITDA margins approaching 40% indicate a highly profitable, scalable business model.
- Clear Capex Plan: Utilizing the bulk of IPO funds for capacity expansion at Unit-II provides strong visibility for future revenue growth.
- Valuation Comfort: At ~13x P/E, the pricing is highly attractive relative to industry peers and its own growth rates.
Risks:
- Regulatory Vulnerability: The past suspension of operations at Manufacturing Unit-1 by the FDA due to non-compliance highlights severe regulatory risks inherent in pharma manufacturing.
- High Leverage & Cash Flow: The sharp rise in borrowings to ~₹38 Crores and reported negative operating cash flows (due to working capital lockups) require careful monitoring.
- Client Concentration: The top 10 customers contribute over 76% of revenue, making the company vulnerable to the loss of any key B2B client.
Key Considerations for Investors
Investors should note the Minimum Investment structure.
- Minimum Application: The lot size is 1,000 Shares. Based on the data provided, the minimum application for Retail Individual Investors is 2 Lots (2,000 Shares), amounting to ₹2,78,000. Note: This investment amount exceeds the typical ₹2 Lakh retail limit, which implies this category effectively targets Small-HNI investors.
- Valuation vs. Risk: The valuation and growth metrics are stellar, but the history of regulatory suspension at one of its units and negative cash flows are critical structural risks to weigh.
Key Takeaways
- IPO Price: ₹139 per share (Upper Band).
- Min Investment: ₹2,78,000 (2,000 Shares).
- Financials: Revenue ₹38 Cr (FY25); Exceptional RoNW (99%).
- Allotment: May 26, 2026
- Listing: NSE SME platform on May 29, 2026.
Important iPO links
2. iPO Daywise subscription status
3. IPO GMP vs Listing Accuracy Study 2026
4. IPO Listing Performance Tracker 2026 – Complete Dataset of IPO Listing Gains in India
FAQs on Bio Medica Laboratories IPO
What is Bio Medica Laboratories IPO GMP today?
Check the latest gmps of all live and upcoming IPOs.
What is Bio Medica Laboratories IPO price band?
The price band is fixed at ₹132 to ₹139 per equity share.
What is Bio Medica Laboratories IPO allotment date?
The allotment status is expected to be finalized on Tuesday, May 26, 2026.
How to check Bio Medica Laboratories IPO allotment status?
Investors can check the status on the website of Skyline Financial Services Pvt. Ltd. (the Registrar) or via the NSE IPO allotment portal.
What is Bio Medica Laboratories IPO listing date?
The shares are tentatively scheduled to list on Friday, May 29, 2026.
Investment Perspective on Bio Medica Laboratories IPO
Bio Medica Laboratories offers a compelling high-growth, high-margin opportunity in the pharma contract manufacturing space.
While the valuation is extremely attractive and return ratios are market-beating, investors must carefully consider the significant regulatory risks and the high minimum investment ticket size before participating
Disclaimer:
This article is strictly for educational purposes. Please consult a SEBI-registered investment advisor before making any investment decisions.
